RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Purpose: The purpose of this preclinical study was to determine the effectiveness of RAF265, a multikinase inhibitor, for treatment of human metastatic melanoma and to characterize traits associated with drug response. Experimental Design: Advanced metastatic melanoma tumors from 34 patients were orthotopically implanted to nude mice. Tumors that grew in mice (17 of 34) were evaluated for response to RAF265 (40 mg/kg, every day) over 30 days. The relation between patient characteristics, gene mutation profile, global gene expression profile, and RAF265 effects on tumor growth, mitogen-activated protein/extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK) phosphorylation, proliferation, and apoptosis markers was evaluated. Results: Nine of the 17 tumors that successfully implanted (53%) were mutant BRAF (BRAFV600E/K), whereas eight of 17 (47%) tumors were BRAF wild type (BRAFWT). Tumor implants from 7 of 17 patients (41%) responded to RAF265 treatment with more than 50% reduction in tumor growth. Five of the 7 (71%) responders were BRAFWT, of which 1 carried c-KITL576P and another N-RASQ61R mutation, while only 2 (29%) of the responding tumors were BRAFV600E/K. Gene expression microarray data from nonimplanted tumors revealed that responders exhibited enriched expression of genes involved in cell growth, proliferation, development, cell signaling, gene expression, and cancer pathways. Although response to RAF265 did not correlate with pERK1/2 reduction, RAF265 responders did exhibit reduced pMEK1, reduced proliferation based upon reduced Ki-67, cyclin D1 and polo-like kinase1 levels, and induction of the apoptosis mediator BCL2-like 11. Conclusions: Orthotopic implants of patient tumors in mice may predict prognosis and treatment response for melanoma patients. A subpopulation of human melanoma tumors responds to RAF265 and can be characterized by gene mutation and gene expression profiles. Clin Cancer Res; 18(8); 2184–98. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460 · cited 11×
“A recent paper from the Garraway laboratory (18) demonstrated that the MAP3K COT is capable of directly phosphorylating ERK1/2 in melanoma cells.”
InfluentialClusterin inhibits apoptosis by interacting with activated Bax
Zhang, H., Kim, J. K., Edwards, C. A., Xu, Z., Taichman, R., & Wang, C.-Y. (2005) · Nature Cell Biology · doi:10.1038/ncb1291 · Cited by 453
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1577 · Cited by 262 · cited 3×
“The gene expression profile we identified in association with RAF265 nonresponsive tumors is quite different from that identified by Dry (35) to be associated with resistance to inhibitors of MEK, with the following exceptions: SPRY2, CD44, and CLU from the Dry analysis were also in the RMA/ limma statistical analysis…”
Cragg, M. S., Jansen, E. S., Cook, M., Harris, C., Strasser, A., & Scott, C. L. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35437 · Cited by 207
Su, Z., Dias-Santagata, D., Duke, M., Hutchinson, K., Lin, Y.-L., Borger, D. R., Chung, C. H., Massion, P. P., Vnencak-Jones, C. L., Iafrate, A. J., et al. (2011) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.010 · Cited by 176
Cited by
Vemurafenib: the first drug approved for BRAF-mutant cancer
Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K., & Hirth, P. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3847 · Cited by 822
Girotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.006 · Cited by 212
“Critically, a PDX from this patient is resistant to dabrafenib plus trametinib but sensitive to CCT196969 and CCT241161 (Figure 6C), and no body weight loss was observed in the mice (Figure S6B).”
Wei, C.-Y., Zhu, M.-X., Yang, Y.-W., Zhang, P.-F., Yang, X., Peng, R., Gao, C., Lu, J.-C., Wang, L., Deng, X.-Y., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0711-z · Cited by 161
Treatment of NRAS-mutant melanoma
Johnson, D. B., & Puzanov, I. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0330-z · Cited by 139
Vilgelm, A. E., Pawlikowski, J. S., Liu, Y., Hawkins, O. E., Davis, T. A., Smith, J., Weller, K. P., Horton, L. W., McClain, C. M., Ayers, G. D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2405 · Cited by 115
“Generation of patient-derived xenograft (PDX) was approved by the Institutional Review Board and has been described previously (22).”
MethodSelf-citation
Metadata
- Authors
- Su, Y., Vilgelm, A. E., Kelley, M. C., Hawkins, O. E., Liu, Y., Boyd, K. L., Kantrow, S., Splittgerber, R. C., Short, S. P., Sobolik, T., Zaja-Milatovic, S., Dahlman, K. B., Amiri, K. I., Jiang, A., Lu, P., Shyr, Y., Stuart, D. D., Levy, S., Sosman, J. A., & Richmond, A.
- Venue
- Clinical Cancer Research
- Published
- 2012-04-15
- Volume
- 18
- Issue
- 8
- Pages
- 2184-2198
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2119081353
- Cited by
- 62
- References
- 6
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-1122
- The paper
- Su, Y., Vilgelm, A. E., Kelley, M. C., Hawkins, O. E., Liu, Y., Boyd, K. L., Kantrow, S., Splittgerber, R. C., Short, S. P., Sobolik, T., Zaja-Milatovic, S., Dahlman, K. B., Amiri, K. I., Jiang, A., Lu, P., Shyr, Y., Stuart, D. D., Levy, S., Sosman, J. A., & Richmond, A. (2012). RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-1122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.